Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Takeda Pharmaceutical CO Ltd (TAK)

Takeda Pharmaceutical CO Ltd (TAK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,950,710
  • Shares Outstanding, K 1,562,360
  • Annual Sales, $ 18,875 M
  • Annual Income, $ 982,130 K
  • 60-Month Beta 0.69
  • Price/Sales 1.42
  • Price/Cash Flow 7.81
  • Price/Book 0.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.69
  • Growth Rate Est. (year over year) +144,682.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.12 +0.76%
on 07/23/19
18.16 -5.01%
on 07/11/19
-0.20 (-1.15%)
since 06/21/19
3-Month
16.46 +4.80%
on 06/06/19
19.85 -13.10%
on 05/10/19
-1.16 (-6.30%)
since 04/23/19
52-Week
15.50 +11.29%
on 12/18/18
21.95 -21.41%
on 09/14/18
-3.92 (-18.52%)
since 07/23/18

Most Recent Stories

More News
Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates

Seattle Genetics (SGEN) betters loss estimates and rides high on revenue beat in Q2.

MRK : 82.03 (+1.01%)
SGEN : 75.95 (-0.16%)
RHHBY : 33.9300 (+0.71%)
TAK : 17.25 (+0.52%)
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or "the Company")...

SHPG : 179.20 (+4.10%)
TKPYY : 16.5900 (-0.90%)
TAK : 17.25 (+0.52%)
J&J Submits BLA for Subcutaneous Formulation of Darzalex

Johnson & Johnson (JNJ) submits a BLA to the FDA, seeking approval for a subcutaneous formulation of its multiple myeloma drug.

CELG : 89.82 (+0.39%)
JNJ : 128.84 (+0.16%)
RHHBY : 33.9300 (+0.71%)
TAK : 17.25 (+0.52%)
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or "the Company")...

SHPG : 179.20 (+4.10%)
TKPYY : 16.5900 (-0.90%)
TAK : 17.25 (+0.52%)
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or "the Company")...

SHPG : 179.20 (+4.10%)
TKPYY : 16.5900 (-0.90%)
TAK : 17.25 (+0.52%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK

Pomerantz LLP is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or the "Company") (NYSE: TAK). Such investors are advised to contact Robert S. Willoughby...

TKPYY : 16.5900 (-0.90%)
TAK : 17.25 (+0.52%)
Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status

The FDA grants orphan drug designation to Arcturus Therapeutics' (ARCT) candidate, ARCT-810 for treating patients with ornithine transcarbamylase deficiency, the most common urea cycle disorder.

RARE : 60.32 (-4.42%)
JNJ : 128.84 (+0.16%)
ARCT : 11.49 (-1.12%)
TAK : 17.25 (+0.52%)
J&J's Darzalex Gets FDA Nod for First-Line Multiple Myeloma

Johnson & Johnson's (JNJ) label expansion application, seeking approval for Darzalex+Revlimid to treat transplant ineligible newly diagnosed patients with multiple myeloma, receives FDA approval.

CELG : 89.82 (+0.39%)
JNJ : 128.84 (+0.16%)
RHHBY : 33.9300 (+0.71%)
TAK : 17.25 (+0.52%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK

Pomerantz LLP is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or the "Company") (NYSE: TAK). Such investors are advised to contact Robert S. Willoughby...

TKPYY : 16.5900 (-0.90%)
TAK : 17.25 (+0.52%)
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or "the Company")...

SHPG : 179.20 (+4.10%)
TKPYY : 16.5900 (-0.90%)
TAK : 17.25 (+0.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade TAK with:

Business Summary

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide...

See More

Key Turning Points

2nd Resistance Point 17.42
1st Resistance Point 17.33
Last Price 17.25
1st Support Level 17.14
2nd Support Level 17.04

See More

52-Week High 21.95
Fibonacci 61.8% 19.49
Fibonacci 50% 18.73
Fibonacci 38.2% 17.96
Last Price 17.25
52-Week Low 15.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar